Facebook Twitter LinkedIn Email

Thrombosis

Last updated: November 16, 2020

On this page:

The following is a curated review of key information and literature about this topic. It is not comprehensive of all data related to this subject.

Overview

Although respiratory manifestations predominate in patients with COVID-19, other systems can also be affected. Early in the pandemic, international reports suggested a high rate of venous thromboembolism (VTE) (Chen, April 2020; Klok, April 2020; Lodigiani, April 2020). These reports were confounded by a lack of uniform use of VTE prophylaxis, heterogeneous populations (ICU vs non-ICU patients), and lack of prospective evaluation for VTE. 

As the pandemic has progressed, additional data suggests the incidence of VTE in hospitalized patients with COVID-19 is high, with reported incidences of up to 16% in the U.S. (Bilaloglu, July 2020). Autopsy series have found evidence of small vessel thrombosis and microangiopathy in the lungs, as well as VTE;  these studies were performed with patients who had severe disease (Lax, May 2020; Fox, July 2020; Wichmann, Aug 2020).  

Procoagulant responses likely result from specific interactions between host defense mechanisms and the coagulation system (Iba, September 2020). Multiple mechanisms may be implicated in COVID-19 patients who develop a pro-coagulative state in COVID-19. D-dimer is often elevated (Berger, August 2020; Iba, September 2020), and several case series/reports have noted increased factor VIII and von Willebrand factor (Escher, April 2020), complement activation (Margo, April 2020), platelet activation (Manne, June 2020), increase in fibrinogen (Panigada, April 2020), and neutrophil extracellular traps (Middleton, September 2020). Some studies have also found antiphospholipid antibodies in patients with COVID-19 (Helms, April 2020;Zhang, April 2020; Bowles, July 2020), and heparin resistance (White, May 2020).

Below, we review select epidemiologic literature evaluating the coagulative state of patients with COVID-19. Multiple studies on this topic have been published; here we have focused on the largest studies and studies with the highest level of evidence and the most generalizable results.   

Guidelines

The American Thoracic Society recommends all hospitalized patients with COVID-19 should receive thromboprophylaxis therapy, unless otherwise contraindicated.

  • Low-molecular-weight heparin or fondaparinux should be used for thromboprophylaxis over unfractionated heparin and direct oral anticoagulants.
  • There are insufficient data to justify routine increased intensity anticoagulant dosing in hospitalized or critically ill COVID-19 patients.
  • Thromboprophylaxis for COVID-19 patients is not indicated in the outpatient setting
  • In critically ill COVID-19 patients, suggest against routine ultrasound screening for the detection of asymptomatic deep vein thrombosis (DVT).
  • For critically ill COVID-19 patients with proximal DVT or pulmonary embolism, recommend parenteral anticoagulation therapy with therapeutic weight adjusted low-molecular-weight heparin or fondaparinux over unfractionated heparin.

The American Society of Hematology recommends all hospitalized adults with COVID-19 receive pharmacologic thromboprophylaxis with low molecular weight heparin over unfractionated heparin (to reduce contact).

  • Due to a lack of high-quality evidence, the use of empiric intermediate or high dose anticoagulation is recommended only in the context of a clinical trial.
  • American Society of Hematology Guidelines on the use of anticoagulation for patients with COVID-19 are forthcoming.

 

Key Literature 

In summary: Clinicians should have a high clinical suspicion for thrombotic events in COVID-19 patients, given the potential of a hypercoagulable state and the apparently high incidence of thrombosis in admitted patients, particularly in the ICU setting. Whether critically ill COVID-19 patients should receive therapeutic anticoagulation in the absence of confirmed or suspected venous thromboembolism is currently unknown. Several randomized controlled trials are investigating the effects of different doses of heparin on COVID-19 patient outcomes; results are forthcoming.

 

Anticoagulation, Bleeding, Mortality and Pathology in Hospitalized Patients With COVID-19 (Nadkarni, October 2020).

Study population:

  • 4,389 patients with laboratory-confirmed SARS-CoV-2 infection in 5 New York City hospitals.
    • 900 patients received therapeutic anticoagulation, 1,959 patients received prophylactic anticoagulation and 1,530 patients did not receive anticoagulation.
    • Patients who received both therapeutic and prophylactic anticoagulation during the admission were excluded.
  • The median age was 65 years (interquartile range: 53-77 years), 44% were women, 26% self-identified as African American and 27% as Hispanic/Latinx.
  • 8% of the sample had hypertension and 22.6% had diabetes.
  • Approximately one-tenth of the total cohort were on anticoagulation or antiplatelet medications prior to admission (1.8% and 8.5%, respectively).
  • The median initial D-dimer was 1.7 (IQR 0.9-3.6).
  • D-dimer concentrations were highest in the patients who received therapeutic anticoagulation (median 2.3 μg/ml; interquartile range: 1.2 to 5.8 μg/ml).
  • On hospital presentation, patients in the therapeutic anticoagulation group had higher blood pressures, faster heart and respiratory rates and lower oxygen saturation.

Primary endpoint:

  • In-hospital mortality.

Key findings:

  • Therapeutic anticoagulation (n = 900; 20.5%) and prophylactic anticoagulation (n = 1,959; 44.6%) were associated with lower in-hospital mortality (aHR, 0.53; 95% CI, 0.45 to 0.62 and aHR, 0.50; 95% CI, 0.45 to 0.57, respectively) and intubation (aHR, 0.69; 95% CI, 0.51 to 0.94 and aHR, 0.72; 95% CI, 0.58 to 0.89, respectively), compared to no anticoagulation (n = 1,530; 34.9%).
  • When initiated ≤48 h from admission, there was no statistically significant difference in mortality between therapeutic (n = 766) versus prophylactic anticoagulation (n = 1,860) (aHR, 0.86; 95% CI, 0.73 to 1.02; p = 0.08).
  • 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic and 29 of 1,530 (1.9%) on no anticoagulation.
  • Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of those 11 (27%) were on therapeutic anticoagulation.

Limitations:

  • This was a retrospective observational study; bias is possible.
  • Baseline characteristics in the patients who received therapeutic versus prophylactic anticoagulation were not well balanced. Notably, patients who received therapeutic anticoagulation were older and had more comorbid conditions.
  • There may be a higher proportion of patients on anticoagulation as compared to other institutions, as Mount Sinai initiated a system-wide protocol (wherein at least prophylactic anticoagulation was strongly encouraged with guidance provided for consideration of therapeutic anticoagulation based on various factors).
  • Patients who received less than 48 hours of therapeutic anticoagulation were categorized as not treated with anticoagulation.
  • It is not clear how the decision to use therapeutic anticoagulation (as opposed to prophylactic anticoagulation) was made. It was dependent on the treating physician.

Overall, in this retrospective study evaluating the association of anticoagulation on in-hospital outcomes in patients with COVID-19, there was an association of lower mortality and intubation in patients receiving therapeutic and prophylactic anticoagulation compared to no anticoagulation. There was a trend toward decreased mortality with therapeutic anticoagulation compared with prophylactic anticoagulation; this was not statistically significant. The study is limited by a lack of balance in baseline characteristics.

 

Incidence of thrombotic complications in critically ill ICU patients with COVID-19 (Klok, July 2020).

Study population:

  • Retrospective study of 184 COVID-19 patients in ICU at 3 Dutch hospitals.

Primary endpoint:

  • The incidence of a composite outcome of symptomatic acute pulmonary embolism, deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism.

Key findings:

  • The cumulative incidence of the composite outcome was 31% (95% CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%).
  • Pulmonary embolism was the most frequent thrombotic complication (n = 25, 81%).

Limitations:

  • This was a retrospective study, with the potential for confounding.
  • VTE screening was not employed; therefore, incidence may have been higher.

 

Retrospective cohort study of thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System (Bilaloglu, July 2020).

Study population:

  • 3334 hospitalized patients with COVID-19 at a single health system in New York City.

Primary endpoint:

  • Incidence of, and risk factors for, venous and arterial thrombotic events.

Key findings:

  • Thrombotic event(s) were documented in 533 patients (16%).
  • 207 of the events (6.2%) were VTE, and 365 (11.1%) were arterial (1.6% ischemic stroke, 8.9% MI, and 1.0% systemic thromboembolism).
  • In 829 critically ill patients, 29.4% had a thrombotic event; among 2505 non-critically ill patients, 11.5% had a thrombotic event.
  • On multivariate analysis, factors associated with increased thrombosis risk were: older age, male gender, Hispanic ethnicity, coronary artery disease, prior myocardial infarction, and high D-dimer (> 500 ng/ml) on presentation.
  • All-cause mortality was 24.5%, and was higher in those with thrombotic events (43.2% vs 21.0%; P <0 .001).
  • A thrombotic event was independently associated with mortality (adjusted hazard ratio, 1.82; P <0 .001).

Limitations:

  • The retrospective nature of the study design may have introduced confounding into the results.
  • Patients were not prospectively assessed for thrombotic complications; subclinical thrombi may have been missed.
  • The study took place in a single health system, which may limit the generalizability of the results.

 

Incidence of Deep Vein Thrombosis among non‐ICU Patients Hospitalized for COVID‐19 Despite Pharmacological Thromboprophylaxis (Santoliquido, July 2020).

Study population:

  • 84 non-critically ill patients admitted consecutively to a hospital in Italy.
  • All patients received prophylactic doses of either enoxaparin or fondaparinux.

Primary endpoint:

  • Incidence of VTE (determined by screening of all patients with ultrasound, regardless of signs or symptoms of VTE) among non-ICU patients hospitalized for COVID-19 who received pharmacological thromboprophylaxis.

Key findings:

  • Seventy-two patients (85.7%) had respiratory insufficiency, required supplemental oxygen, and had reduced mobility/were bedridden.
  • The incidence of DVT was 11.9% (10/84).

Limitations:

  • This was a small, single-center study; the results may not be generalizable.
  • 7% of patients had a history of cancer or current cancer, and 9.5% of patients had recent trauma and/or surgery; this may have confounded the results.
  • Ultrasound was not performed at admission, but was performed early during hospitalization. It is possible DVT was present upon admission, or that DTVs developed later in the hospitalization (and thus not captured).

 

COVID-19 and coagulation: retrospective study of bleeding and thrombotic manifestations of SARS-CoV-2 infection (Al-Samkari, June 2020). 

Study population:

  • 400 patients with COVID-19 admitted to hospitals in a Massachusetts health system.

Study endpoint:

  • Incidence of radiographically confirmed VTE, probable VTE (defined as a consistent clinical syndrome prompting the initiation of anticoagulation in patients unable to have imaging), and clinically significant non-vessel thrombotic events.

Key findings: 

  • The overall thrombotic complication rate was 9.5%.
  • The thrombotic complication rate in noncritically ill patients was 4.7%, and 18.1% in critically ill patients.
  • The overall rate of radiographically-confirmed VTE was 4.8% (3.1% in noncritically ill patients and 7.6% in critically ill patients).
  • All patients but one with VTE were receiving either prophylactic or full-dose anticoagulation.
  • The incidence of arterial thrombotic events was 2.8% - all these patients were receiving prophylactic or full-dose anticoagulation.
  • In multivariate analysis, thrombosis was primarily associated with inflammatory markers, rather than coagulation parameters.

Limitations:

  • The retrospective nature of the study design may have introduced confounding.
  • Patients were not prospectively assessed for thrombotic complications; subclinical thrombi may have been missed.
  • The study took place in a single health system, which may limit the generalizability of the results.

 

Venous thromboembolism (VTE) in COVID-19: systematic review of reported risks and current guidelines (Fontana, June 2020).

Study population:

  • 1369 hospitalized patients with COVID-19 derived from 11 studies (1 clinical trial, 7 retrospective cohorts and 3 prospective cohorts).

Primary endpoint:

  • Systematic review; N/A.

Key findings: 

  • Risk of VTE ranged from 4.4–8.2% in all hospitalized COVID-19 inpatients.
  • In critically ill patients, incidence ranged from 0-35.5%.
  • Two studies at least partially screened for VTE in ICU inpatients with COVID-19, and found incidences of 24.7–53.8%.

Limitations:

  • The study populations in the included papers were heterogeneous in terms of critically ill vs non-critically ill patients.
  • The quality of the studies included was variable.
  • Most, but not all studies reported universal VTE prophylaxis.

 

Prevalence of venous thromboembolism (VTE) in patients with severe novel coronavirus pneumonia (Cui, May 2020).

Study population:

  • Retrospective study of 81 hospitalized ICU patients with severe COVID-19 in China.
  • Thirty‐three patients (41%) had chronic medical conditions, including hypertension, diabetes, and coronary heart disease.

Primary endpoint:

  • To determine the incidence of VTE in patients with severe COVID-19.

Key findings:

  • The incidence of VTE was 25% (20/81), and 8 patients with VTE events died.
  • Patients who developed VTE vs. non-VTE were older, had lower lymphocyte counts, longer activated partial thromboplastin time (aPTT) (39.9 ± 6.4 vs. 35.6 ± 4.5 seconds, P = 0.001), and higher D‐dimer (5.2 ± 3.0 versus 0.8 ± 1.2 µg/mL, P < 0.001).
  • If 1.5 µg/mL was used as the D‐dimer cut‐off value to predicting VTE, the sensitivity was 85.0%, the specificity was 88.5%, and the negative predictive value (NPV) was 94.7%.

Limitations:

  • This was a retrospective, single‐center study with a small sample size and the potential for confounding, limiting generalizability.

 

Additional Literature

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 (Paranjpe, July 2020): In this retrospective single health-system study in New York City, the association between administration of in-hospital anticoagulation was assessed in 2,773 hospitalized patients. Of these, 786 (28%) received therapeutic anticoagulation. In-hospital mortality for patients treated with anticoagulation was 22.5% with a median survival of 21 days, compared to 22.8% and median survival of 14 days in patients who did not receive therapeutic anticoagulation. Patients who received therapeutic AC were more likely to require invasive mechanical ventilation (29.8% vs. 8.1%; p<0.001) as compared to those who received prophylactic dose anticoagulation or did not receive anticoagulation. In patients who required mechanical ventilation (n = 395), in-hospital mortality was 29.1% with a median survival of 21 days for those treated with therapeutic anticoagulation as compared to 62.7% with a median survival of 9 days in patients who did not receive treatment-dose anticoagulation. In a multivariate proportional hazards model, longer duration of anticoagulation treatment was associated with a reduced risk of mortality (aHR 0.86 per day; p<0.001).

 

Resources

Sign up for IDSA's Newsletter
Stay informed with daily resources, media and news.

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.